Jiangsu Recbio Technology Co Ltd Class H 02179
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 9.20
- Day Range
- HKD 8.91–9.20
- 52-Week Range
- HKD 7.95–14.60
- Bid/Ask
- HKD 8.71 / HKD 0.00
- Market Cap
- HKD 4.30 Bil
- Volume/Avg
- 4,500 / 16,151
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 472
- Website
- https://www.recbio.cn
Comparables
Valuation
|
Metric
|
02179
|
300841
|
688670
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 14.03 | 23.83 |
Price/Book Value | 4.78 | 2.33 | 1.62 |
Price/Sales | — | 5.18 | 55.48 |
Price/Cash Flow | — | 12.72 | 75.63 |
Price/Earnings
02179
300841
688670
Financial Strength
|
Metric
|
02179
|
300841
|
688670
|
|---|---|---|---|
Quick Ratio | 3.86 | 4.14 | 1.40 |
Current Ratio | 3.99 | 4.49 | 3.34 |
Interest Coverage | −84.89 | 119.95 | −80.32 |
Quick Ratio
02179
300841
688670
Profitability
|
Metric
|
02179
|
300841
|
688670
|
|---|---|---|---|
Return on Assets (Normalized) | −23.96% | — | −4.87% |
Return on Equity (Normalized) | −46.33% | — | −5.91% |
Return on Invested Capital (Normalized) | −30.73% | — | −5.65% |
Return on Assets
02179
300841
688670
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hqnjflnln | Srb | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xntmkqqkc | Pljjt | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sfkddntkv | Bxfdvqh | $107.6 Bil | |
MRNA
| Moderna Inc | Gcvxgkzc | Vjkls | $47.0 Bil | |
ARGX
| argenx SE ADR | Vzfhkbpx | Yygj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dfbdfqrm | Dldky | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qdqlmpzg | Ffbzl | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vsrvqkbql | Wtgqgp | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lmqxjmylpg | Nzjktn | $12.7 Bil | |
INCY
| Incyte Corp | Gldgjtgv | Spwdygv | $12.0 Bil |